Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women's reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
Industry, Sector and Symbol:
- Sector: Finance
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:DARE
- CUSIP: N/A
- Web: www.darebioscience.com
Capitalization:- Market Cap: $16.93 million
- Outstanding Shares: 2,903,000
Average Prices:- 50 Day Moving Avg: $4.87
- 200 Day Moving Avg: $7.60
- 52 Week Range: $2.63 - $35.80
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.19
- P/E Growth: 0.00
Profitability:- Return on Equity: -244.69%
- Return on Assets: -99.67%
Debt:- Current Ratio: 2.43%
- Quick Ratio: 2.34%
Misc:- Average Volume: 175,083 shs.
- Beta: 2.56
Frequently Asked Questions for Cerulean Pharma (NASDAQ:DARE)
What is Cerulean Pharma's stock symbol?
Cerulean Pharma trades on the NASDAQ under the ticker symbol "DARE."
How were Cerulean Pharma's earnings last quarter?
Cerulean Pharma Inc. (NASDAQ:DARE) released its quarterly earnings data on Thursday, August, 4th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.08. View Cerulean Pharma's Earnings History.
When will Cerulean Pharma make its next earnings announcement?
Where is Cerulean Pharma's stock going? Where will Cerulean Pharma's stock price be in 2017?
4 brokerages have issued 1-year target prices for Cerulean Pharma's shares. Their predictions range from $1.50 to $6.00. On average, they anticipate Cerulean Pharma's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Cerulean Pharma.
Who are some of Cerulean Pharma's key competitors?
Some companies that are related to Cerulean Pharma include Redx Pharma PLC (REDX), ANGLE plc (AGL), Auris Medical Holding AG (EARS), Zosano Pharma Corporation (ZSAN), Nivalis Therapeutics (ALPN), Dimension Therapeutics (DMTX), Ampio Pharmaceuticals (AMPE), Alcobra (ADHD), Viking Therapeutics (VKTX), Eleven Biotherapeutics (EBIO), Vical Incorporated (VICL), Catabasis Pharmaceuticals (CATB), Inotek Pharmaceuticals Corporation (ITEK), Capricor Therapeutics (CAPR), Proteon Therapeutics (PRTO), Aviragen Therapeutics (AVIR), Biopharmx Corp (BPMX) and Biopharmx Corp (BPMX).
Who are Cerulean Pharma's key executives?
Cerulean Pharma's management team includes the folowing people:
- Roger L. Hawley, Independent Chairman of the Board
- Sabrina Martucci Johnson, President, Chief Executive Officer, Secretary, Director
- Gregg D. Beloff J.D., Principal Financial Officer
- Lisa Walters-Hoffert, Chief Financial Officer
- Jame O'Neill, Principal Accounting Officer, Controller, Assistant Treasurer
- William H. Rastetter Ph.D., Lead Independent Director
- Steve E. Hall Ph.D., Independent Director
- Susan L. Kelley M.D., Independent Director
- Robin J. Steele J.D., Independent Director
How do I buy Cerulean Pharma stock?
Shares of Cerulean Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cerulean Pharma's stock price today?
One share of Cerulean Pharma stock can currently be purchased for approximately $2.76.
MarketBeat Community Rating for Cerulean Pharma (NASDAQ DARE)MarketBeat's community ratings are surveys of what our community members think about Cerulean Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cerulean Pharma (NASDAQ:DARE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $3.00 (8.70% upside) |
Analysts' Ratings History for Cerulean Pharma (NASDAQ:DARE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/9/2016 | Canaccord Genuity | Reiterated Rating | Buy | $6.00 | N/A |  |
| 10/23/2016 | Roth Capital | Reiterated Rating | Buy | $2.50 | N/A | |
| 10/19/2016 | Leerink Swann | Reiterated Rating | Market Perform | $1.50 | N/A | |
| 8/30/2016 | Barclays PLC | Lower Price Target | Overweight | $5.00 -> $2.00 | N/A | |
| 8/18/2016 | Wedbush | Downgrade | Outperform -> Neutral | | N/A | |
| 8/18/2016 | Janney Montgomery Scott | Downgrade | Buy -> Neutral | | N/A | |
| 3/9/2016 | J P Morgan Chase & Co | Boost Price Target | Market Outperform | $9.00 -> $16.00 | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $16.00 -> $9.00 | N/A | |
(Data available from 8/19/2015 forward)
Earnings History for Cerulean Pharma (NASDAQ:DARE)Earnings History by Quarter for Cerulean Pharma (NASDAQ DARE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | | | | | | | |
| 8/4/2016 | Q216 | ($0.48) | ($0.40) | | | View | N/A | |
| 5/2/2016 | Q116 | ($0.43) | ($0.49) | | | View | N/A | |
| 3/10/2016 | Q415 | ($0.41) | ($0.39) | | | View | Listen | |
| 11/16/2015 | Q315 | ($0.41) | ($0.39) | | | View | Listen | |
| 8/6/2015 | Q215 | ($0.40) | ($0.37) | | | View | N/A | |
| 3/19/2015 | Q4 2014 | ($0.36) | ($0.37) | | | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.32) | ($0.28) | | | View | N/A | |
| 8/12/2014 | Q2 2014 | ($0.36) | ($0.34) | | $0.03 million | View | N/A | |
| 5/27/2014 | Q1 2014 | ($3.52) | ($3.70) | | $0.05 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cerulean Pharma (NASDAQ:DARE)Current Year EPS Consensus Estimate: $-14.2 EPS
Next Year EPS Consensus Estimate: $-14.3 EPS
Dividend History for Cerulean Pharma (NASDAQ:DARE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cerulean Pharma (NASDAQ:DARE)Insider Ownership Percentage: 28.60%
Insider Trades by Quarter for Cerulean Pharma (NASDAQ:DARE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/22/2016 | David R Walt | Director | Buy | 2,291 | $2.08 | $4,765.28 | |
| 2/18/2016 | David R. Walt | Director | Buy | 8,960 | $2.10 | $18,816.00 | |
| 2/16/2016 | David R. Walt | Director | Buy | 8,811 | $2.00 | $17,622.00 | |
| 2/11/2016 | David R. Walt | Director | Buy | 8,850 | $2.05 | $18,142.50 | |
| 2/9/2016 | David R. Walt | Director | Buy | 9,000 | $2.15 | $19,350.00 | |
| 2/5/2016 | David R. Walt | Director | Buy | 8,563 | $2.30 | $19,694.90 | |
| 2/3/2016 | David R. Walt | Director | Buy | 8,413 | $2.32 | $19,518.16 | |
| 2/1/2016 | David R. Walt | Director | Buy | 5,700 | $2.38 | $13,566.00 | |
| 1/28/2016 | David R. Walt | Director | Buy | 9,000 | $2.46 | $22,140.00 | |
| 1/26/2016 | David R. Walt | Director | Buy | 8,800 | $2.39 | $21,032.00 | |
| 1/25/2016 | David R. Walt | Director | Buy | 4,500 | $2.35 | $10,575.00 | |
| 1/22/2016 | David R. Walt | Director | Buy | 9,000 | $2.28 | $20,520.00 | |
| 1/20/2016 | David R. Walt | Director | Buy | 8,900 | $2.43 | $21,627.00 | |
| 1/15/2016 | David R. Walt | Director | Buy | 8,572 | $2.53 | $21,687.16 | |
| 1/13/2016 | David R. Walt | Director | Buy | 8,684 | $2.79 | $24,228.36 | |
| 1/11/2016 | David R. Walt | Director | Buy | 8,855 | $2.87 | $25,413.85 | |
| 1/7/2016 | David R. Walt | Director | Buy | 8,800 | $2.95 | $25,960.00 | |
| 1/5/2016 | David R. Walt | Director | Buy | 8,801 | $3.03 | $26,667.03 | |
| 11/30/2015 | David R Walt | Director | Buy | 5,374 | $3.25 | $17,465.50 | |
| 11/27/2015 | David R. Walt | Director | Buy | 12,117 | $3.32 | $40,228.44 | |
| 4/7/2015 | Cvf, Llc | Major Shareholder | Buy | 333,333 | $6.00 | $1,999,998.00 | |
| 4/15/2014 | Alan L Crane | Director | Buy | 1,470,582 | $7.00 | $10,294,074.00 | |
| 4/15/2014 | Eli & Co Lilly | Major Shareholder | Buy | 733,445 | $7.00 | $5,134,115.00 | |
| 4/15/2014 | Lux Capital Management, Llc | Insider | Buy | 106,224 | $7.00 | $743,568.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cerulean Pharma (NASDAQ:DARE)
Latest Headlines for Cerulean Pharma (NASDAQ:DARE)
| Source: |
|
Cerulean Pharma (DARE) Chart for Saturday, August, 19, 2017
